29.04.2015 • NewsDede WillamsEvoniksuperabsorbent polymers

Evonik Inaugurates €1 Million Super Absorbers Center

German chemical producer Evonik has inaugurated a new €1 million application technology center for superabsorbent polymers in Krefeld, Germany.

Evonik said the enlarged laboratory strengthens its position as an innovative solutions provider for superabsorbent polymers, allowing implementation of the newest test methods, which will further strengthen product knowledge and target-oriented innovation efforts.

The new facility is equipped for the evaluation of superabsorbent polymers and hygiene articles, such as the new EDANA mannequin test for incontinence articles.

For the first time, the company said, this test allows the application of realistic in-use conditions to the standardized lab evaluation. It is also open to customers for training and testing sessions.

"Our customers will directly benefit from an even further improved technical service," said Norbert Westerholt, head of Evonik's Baby Care Business Line. The service capabilities of the German company are the industry-wide benchmark and the basis for strong partnerships and development collaborations with its customers, he said.

As one of the leading suppliers of superabsorbent polymers with manufacturing plants in the US, Germany and Saudi Arabia, the Evonik business employs more than 600 people worldwide.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read